ArticleNutrients2026
Transcriptomic Profiling of Sea Buckthorn (
Article in Nutrients, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
BACKGROUND/
objectiveSea buckthorn contains an exceptionally rich profile of bioactive nutrients and metabolites, with established systemic therapeutic benefits across diverse pathological models. However, comprehensive data bridging these systemic outcomes with specific tissue responses are still lacking. This descriptive transcriptomic study establishes a predictive framework to guide the future application of sea buckthorn and its isolated derivatives in targeted preventive and therapeutic strategies.
methodsWe utilized a 3D spheroid culture of normal human amniotic epithelial stem cells (hAESCs) to evaluate the bioactivity effects of sea buckthorn juice (SBJ) treatment.
resultsMicroarray analysis validated spheroid structural growth by revealing the upregulation of key upstream markers of proliferation. This SBJ-induced proliferation was supported by a coordinated upregulation of mitochondrial machinery, including oxidative phosphorylation, mitochondrial RNA processing, the TCA cycle, and mitochondrial membrane organization. Cell type signature analysis revealed that treated cells acquired highly proliferative and active extracellular matrix (ECM) remodeling traits. Furthermore, tissue database mapping showed that the cells shared strong transcriptional similarity with human embryo and Wharton's jelly proliferative states. Muscle-type signatures, including cardiomyocyte, myoblast, and smooth muscle lineages, were consistently enriched.
conclusionsOverall, these findings provide a transcriptomic signature-based predictive model for the biological effects of SBJ. Based on gene ontology and tissue-specific enrichment profiles, our data offer hypothesis-generating predictions suggesting a potential role for SBJ in supporting cellular regeneration via stem cell proliferation. Furthermore, tissue-specific analysis indicates a putative capacity to modulate smooth muscle integrity, inferred from transcriptomic similarities with muscle-type gene signatures. While pure extracted compounds demonstrate beneficial effects, evaluating the whole SBJ matrix provides a broader understanding of its full, unique profile of bioactive properties. These in vitro findings highlight the potential value of the complete juice matrix, forming a predictive baseline for future in vivo and clinical evaluations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.